Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Orphazyme A/S’s (NASDAQ:ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less…
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C
CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today
These OTC Securities Had the Most Trading Activity in June
Photo by Cris Ovalle on Unsplash
OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as volumes in crypto and cannabis slowed.
CytRx Comments On Orphazyme Complete Response Letter From FDA
CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S
Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug
Orphazyme A/S (NASDAQ: ORPH) shares, which have been extremely volatile of late, could come under pressure Friday
A Look At Orpahzyme’s Volatility Ahead Of Thursday’s PDUFA Catalyst
After sobering down in the past three sessions, shares of Danish biopharma Orphazyme A/S (NASDAQ: ORPH) have taken off yet again.
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc.
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.